Document Type

Article

Publication Date

9-29-2025

Comments

This article is the author's final published version in Journal of Medical Economics, Volume 28, Issue 1, 2025, Pages 1696 - 1708.

The published version is available at https://doi.org/10.1080/13696998.2025.2564576. Copyright © 2025 The Author(s).

Abstract

AIM: To optimize the real-world applicability of a health economic model estimating the cost-effectiveness of corneal cross-linking for the treatment of keratoconus in the United States.

MATERIALS AND METHODS: A previously reported discrete-event simulation (DES) model was adapted to reassess the cost-effectiveness of corneal cross-linking (CXL) from the US payer perspective. The simulation of keratoconus progression, which is a key driver of model outcomes, was remodeled to more accurately reflect the real-world relationship between age and the rate of disease progression. All costs were updated to reflect 2025 values. We simulated 4,000 eyes of 2,000 patients diagnosed with keratoconus to compare the lifetime cost and quality-adjusted life years (QALYs) of those treated with CXL vs conventional management.

RESULTS: Given updated cost and disease progression parameters, CXL resulted in lower direct medical costs of $38,897 and 2.97 incremental QALYs over a lifetime treatment horizon. Economically justifiable price (EJP) analysis demonstrated that CXL remained cost-effective up to a drug acquisition cost of $172,369 at a $100,000/QALY cost-effectiveness threshold and $246,549 at a $150,000/QALY cost-effectiveness threshold.

CONCLUSIONS: After modeling a conservative cost of corneal transplantation and incorporating an age-dependent disease progression rate, our evaluation confirmed that CXL was the dominant (i.e. cost-saving and cost-effective) treatment strategy, primarily due to greatly improved patient outcomes (i.e. benefits strongly correlated with visual acuity). As novel and less invasive methods (e.g. transepithelial CXL) enter the market, it is expected that the demand for corneal cross-linking will increase given its significant clinical and economic value.

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

Additional Files
Supplemental Figure 1.jpg (72 kB)
Supplemental Figure 1
Supplemental Figure 2.jpg (40 kB)
Supplemental Figure 2
Supplemental Figure 3.jpg (104 kB)
Supplemental Figure 3

PubMed ID

40981503

Language

English

Download

Share

COinS